Efficient Removal of Aggregates from Monoclonal Antibodies

| December 26, 2018

article image
Monoclonal antibody (mAb) therapeutics have been widely used to treat various diseases, including cancer. Oftentimes, dimers and other high molecular weight aggregates are present in the mAb therapeutics, leading to reduced biological activity. Traditionally-used methods for aggregate removal rely heavily on anion exchange chromatography (AEX) in flow-through mode followed by a generic bind/elute polishing step.

Spotlight

Indicia

As a trusted partner of the Pharma, Diagnostics, Cosmetics and Biotech industries, Indicia offers industrial production services to companies wishing to outsource the formulation, sterilization and packaging of liquid or semi-liquid reagents. This expertise includes in particular the subcontracting production of culture media for Microbiology.

OTHER ARTICLES

5 Pharma Trends and Their Impact on Packaging

Article | February 27, 2020

The pharmaceutical industry is changing at an unprecedented pace. New biological treatments for cancer, and a dramatic rise of widespread diseases such as diabetes, call for new processing and packaging solutions to fulfill the different needs all over the world. Keep your eye on these five main packaging trends for 2020 for the global pharmaceutical market.

Read More

Pfizer Won’t Win the Coronavirus Pharma War

Article | February 27, 2020

Shares of Pfizer jumped more than 6% on Wednesday, after the company announced a plan to test some of its antiviral products as a potential treatment for the coronavirus from China. More than 35 million shares traded on the news — about 48% more than normal — as investors looked for any positive news from the pharma community after the recent selloff. So, does this mean that Pfizer stock is turning the corner?

Read More

Five Ways to Manage Your Trial Effectively in a Fast-Changing Global Environment

Article | February 27, 2020

Over the past half-century, clinical trials have grown increasingly complex. A flood of new data from novel sources combined with more elaborate study designs and tougher regulatory standards have lengthened timelines and hiked costs, contributing to a steady decline of efficiency. It all adds up: Nearly half of all drug launches underperform revenue expectations. And if that isn’t enough, the outbreak of COVID-19 worldwide is having an effect on how life sciences companies operate their businesses, including how clinical trials are conducted. Most clinical trial research organizations have tried to adapt by tweaking a platform here, adding a new app there, but this has only yielded patchwork systems of sites, spreadsheets and dashboards that further burden the process.

Read More

What do you have to lose taking hydroxychloroquine for coronavirus? Potentially your life

Article | February 27, 2020

The president and some of his close advisors — desperate for a COVID-19 cure — are asking “What do you have to lose?” by taking hydroxychloroquine (HCQ), a strong medication never adequately tested for efficacy or safety in COVID-19 patients. The correct answer to the president’s question, which he doesn’t seem to want to hear, is that we have our lives to lose. The president acknowledges “I’m not a doctor” but this raises the question “What do doctors know about the drug recommended by the president? Most doctors are aware that HCQ can be effective for patients with malaria, arthritis or lupus. If they were to follow the president’s suggestion and prescribe it for COVID-19 patients, they would also like to know that it will benefit some of those patients, at least.

Read More

Spotlight

Indicia

As a trusted partner of the Pharma, Diagnostics, Cosmetics and Biotech industries, Indicia offers industrial production services to companies wishing to outsource the formulation, sterilization and packaging of liquid or semi-liquid reagents. This expertise includes in particular the subcontracting production of culture media for Microbiology.

Events